Isolated hepatic perfusion: A potentially effective treatment for patients with metastatic or primary cancers confined to the liver

Cancer Journal from Scientific American

Volumn 4, Issue 1, 1998, Pages 2-11

  Alexander Jr , H Richard ^a,b   Bartlett, David L ^a   Libutti, Steven K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; FOTEMUSTINE; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MELPHALAN; MITOMYCIN; TUMOR NECROSIS FACTOR;

BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FIRST PASS EFFECT; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; HYPERTHERMIA; INTRAARTERIAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; LIVER CANCER; LIVER METASTASIS; LIVER PERFUSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; META ANALYSIS; MULTICENTER STUDY; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGIONAL PERFUSION; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR NECROSIS;

CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 0345244846     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Daly JM, Kemeny NE. Metastaric cancer to the liver. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology (5th ed). Philadelphia: Lippincott-Raven, 1997: 2551-2570.
2. Weiss L, Grundman E, Torhurst J et al. Hemotagenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203.
3. Kath R, Hayungs J, Bornfeld N et al. Prognosis and treatment of disseminated uveal melanoma. Cancer 1993;72:2219-2223.
4. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. Acta Opthalmol (Copenh) 1995; 73:340-344.
5. Carr BI, Flickinger JC, Lotze MT. Hepatobiliary cancers. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology (5th ed). Philadelphia: Lippincott-Raven, 1997:1087-1114.
6. Kemeny N, Seiter K, Conti JA et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma: new dose schedules and survival update. Cancer 1994; 73:1134-1142.
7. Chang AE, Schneider PD, Sugarbaker PH et al. A prospective randomized trial of regional versus systemic continuous fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685-693.
8. Rougier P, LaPlanche A, Huguier M et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992;10:1112-1118.
9. Bedikian AY, Legha SS, Mavligit G et al. Treatment of uveal melanoma metastatic to the liver. Cancer 1995;76:1665-1670.
10. Alexander HR, Bartlett DL, Fraker DL et al. Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. PPO Updates 1996;10:1-19.
11. Pentecost MJ. Transcatheter treatment of hepatic metastases. AJR Am J Roentgenol 1993;160:1171-1175.
12. Ravikumar TS, Pizzorno G, Bodden W et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol 1994;12: 2723-2736.
13. Kemeny N, Seiter K, Niedzwiecki D et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327-334.
14. Kemeny N, Conti JA, Cohen A et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994;12: 2288-2295.
15. Curley SA, Newman RA, Dougherty T et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol 1994;1:389-399.
16. Feun LG, Reddy KR, Yrizzarry JM et al. A phase I study of chemoembolization with cisplatin and lipiodol for primary and metastatic liver cancer. Am J Clin Oncol 1994;17:405-410.
17. Trinchet JC, Rached AA, Beaugrand M. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-1261.
18. Lee MJ, Mueller PR, Dawson SL et al. Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique, and efficacy. AJR Am J Roentgenol 1995;164:215-220.
19. Cuschieri A, Crosthwaite G, Shimi S et al. Hepatic cryotherapy for liver tumors: development and clinical evaluation of a high-efficiency insulated multineedle probe system for open and laparoscopic use. Surg Endosc 1995;9:483-489.
20. Zhou XD, Tang ZY, Yu YQ et al. The role of cryosurgery in the treatment of hepatic cancer: a report of 113 cases. J Cancer Res Clin Oncol 1993;120:100-102.
21. Seki T, Wakabayashi M, Nakagawa T et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 1994;74:817-825.
22. Ausman RK. Development of a technic for isolated perfusion of the liver. NY State J Med 1961;61:3393-3397.
23. Joiner MC, Steel GG, Stephens TC. Response of two mouse tumours to hyperthermia with CCNU or melphalan. Br J Cancer 1982;45:17-26.
24. Kitamura K, Kuwano H, Matsuda H et al. Synergistic effects of intratumor administration of cis-diamminedichloroplatinum(II) combined with local hyperthermia in melanoma bearing mice. J Surg Oncol 1992;51:188-194.
25. Miller RC, Richards M, Baird C et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 1994;10:89-99.
26. Hachiya T, Okada K, Sakurai A et al. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia against heterotransplanted human prostatic carcinoma and its lymph node metastasis in nude mice. Mol Biother 1992;4:34-39.
27. Klostergaard J, Leroux E, Siddik ZH et al. Enhanced sensitivity of human colon tumor cell lines in vitro in response to thermochemoimmunotherapy. Cancer Res 1992;52:5271-5277.
28. Aigner KR, Walther H, Tonn JC et al. Die isolierte leberperfusion bei fortgeschrittenen metastasen kolorektaler karzinome. Onkologie 1984;7:13-21.
29. Marinelli A, de Brauw LM, Beerman H et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 1996;26:341-350.
30. van Zuidewign DBW, de Brauw LM, Marinelli A et al. Isolated liver perfusion with mitomycin-C or melphalan in patients with hepatic metastases [abstract]. Society of Surgical Oncology 1993;46:198.
31. Schwemmle K, Link KH, Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J Surg 1987;11: 534-540.
32. Hafström LR, Holmberg SB, Naredi PLJ et al. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surgical Oncology 1994;3:103-108.
33. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg 1986;121: 1266-1271.
34. Skibba JL, Quebbeman EJ, Komorowski RA et al. Clinical results of hyperthermic liver perfusion for cancer in the liver. In: Aigner KR, Patt YZ, Link KH et al, eds. Regional Cancer Treatment. Basel: Karger, 1988:222-228.
35. Carswell EA, Old LJ, Kassel RL et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-3670.
36. Pennica DG, Nedwin GE, Hayflick JS et al. Human rumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-729.
37. Fraker DL, Alexander HR, Pass HI. Biologic therapy with TNF: systemic administration and isolation-perfusion. In: DeVita V, Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer (2nd ed). Philadelphia: Lippincott, 1995:329-345.
38. Lienard D, Lejeune F, Delmotte J et al. High doses of rTNFα in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992; 10:52-60.
39. Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996;12:416-428.
40. Fraker DL, Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma. In: DeVita VTJ, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: Lippincott, 1994:179-192.
41. Bartlett DL, Ma G, Alexander HR et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer; in press.
42. Fraker DL, Alexander HR, Andrich M et al. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor. Cancer J Sci Am 1995;1:122-130.
43. Fraker DL, Alexander HR, Bartlett DL et al. A prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-gamma (IFN): an initial report [abstract]. Soc Surg Oncol 1996;49:6.
44. Nawroth PP, Bank I, Handley D et al. Tumor necrosis factor/ cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 1086;163:1363-1375.
45. Barker WC, Andrich MP, Alexander HR et al. Continuous intra-operative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med 1995;22:1242-1248.
46. Klaase JM, Kroon BBR, van Geel AN et al. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg 1993;80: 1124-1126.
47. Thom AK, Alexander HR, Andrich MP et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan. J Clin Oncol 1995;13:264-273.
48. Diebel LN, Wilson RF, Bender J et al. A comparison of passive and active shunting for bypass of the retrohepatic IVC. J Trauma 1991;31:987-990.
49. Fraker DL. Isolated hepatic infusion perfusion (IHP) with TNF [abstract]. Cambridge Symposia 1996:11.
50. Hoekstra HJ, Naujocks T, Schraffordt-Koops H et al. Continuous leaking monitoring during hypothermic isolated regional perfusion of the lower limb: techniques and results. Regional Cancer Treatment 1992;4:301-304.
51. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356-362.
52. Hack CE, De Groot ER, Felt-Bersma JF et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989;74:1704-1710.
53. Hack CE, Hart M, van Schijndel RJMS et al. Interleukin-8 sepsis: relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-2842.
54. Alexander HR, Bartlett DL, Libutti SK et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to liver. J Clin Oncol 1998; in press.
55. Leyvraz S, Spataro V, Bauer J et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997;15:2589-2595.